Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 9/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15459018 | 0.91 | APP (0.36) | APPBACE1IMPDH2MAOBIMPDH1 | |
| SCHEMBL13039801 | 0.83 | APP (0.45) | APPBACE1IMPDH2MAOBIMPDH1 | |
| SCHEMBL15459064 | 0.79 | IMPDH2 (0.38) | APPBACE1IMPDH2IMPDH1 | |
| SCHEMBL13039798 | 0.79 | APP (0.42) | APPBACE1IMPDH2IMPDH1SMPD1 | |
| SCHEMBL15459152 | 0.77 | APP (0.39) | APPBACE1IMPDH2IMPDH1 | |
| SCHEMBL15459012 | 0.74 | APP (0.39) | APPBACE1IMPDH2IMPDH1SMPD1 | |
| SCHEMBL12866136 | 0.74 | MAOB (0.56) | APPIMPDH2MAOBPTGESMEN1 | |
| SCHEMBL18253692 | 0.73 | IMPDH2 (0.41) | APPBACE1IMPDH2MAOBIMPDH1 | |
| SCHEMBL15459156 | 0.73 | APP (0.36) | APPBACE1IMPDH2MAOBSMPD1 | |
| SCHEMBL12535804 | 0.72 | APP (0.55) | APPBACE1IMPDH2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140039052-A1 | FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2014-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039052-A1 | FORMULATIONS OF LIPOPHILIC BIOACTIVE MOLECULES | LIPA, LIPC, CEL | APP 1414/4885BACE1 1162/4885IMPDH2 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.